Supplementary Table S3 – Antiviral activity, cytotoxicity, and therapeutic indexes of selected 2-(thio)oxothiazolidin-4-ones (LJ001 and LJ025) and oxazolidine dithiones (JL101-JL122)

Name	$^{(a)}IC_{50} \pm SD (nM) (N=x)$			(b)CC ₅₀ (nM)	(c)TI (NDV)
	HIV	HSV	NDV	PBMC	
LJ001	181.9 ± 244.4 (11)	35.3 ± 48.3 (3)	180.6 ± 104.7 (13)	11,940	66
LJ025	NA	NA	NA	> 50,000	-
JL101	-	-	$8,800 \pm 8,900$ (3)	-	-
JL102	$60.0 \pm 63.1 (5)$	$5.1 \pm 4.8 (4)$	31.8 ± 16.9 (7)	14,780	465
JL103	$12.2 \pm 9.7 (5)$	$1.9 \pm 2.5 (5)$	$5.7 \pm 6.4 (14)$	9,140	1,604
JL108	$10.8 \pm 4.5 (2)$	-	$4.8 \pm 3.0 (5)$	7,050	1,469
JL109	$4.5 \pm 4.8 (3)$	0.7 ± 0.6 (3)	3.8 ± 3.9 (6)	8,510	2,239
JL111	22.0 ± 18.4 (2)	6.0 (1)	$9.4 \pm 4.2 (4)$	-	-
JL117	-	3.2 ± 2.5 (2)	4.3 ± 3.0 (2)	-	-
JL118	$11.7 \pm 5.5 (3)$	$10.1 \pm 8.6 (3)$	2.1 ± 1.4 (6)	37,050	17,643
JL121	NA	NA	NA	> 50,000	-
JL122	$64.0 \pm 41.5 (3)$	2.4 ± 1.4 (5)	0.9 ± 0.8 (2)	10,280	11,422

⁽a) IC₅₀ measured after 10 min of light exposure of the treated viruses. N=x: Number of independent repeats.

NA: Not active.

Cytotoxicity assay. Freshly isolated peripheral blood mononuclear cells (PBMC) were seeded into a 96-wells plate (50,000 cells/well) and incubated for 24h in complete medium (RPMI, 20% FBS, 10 U/ml II-2, 1% Pen/Strep) before treatment with the indicated compounds. Serial dilutions of the compounds were added to the cells, and the plates were exposed to light in the same conditions as viruses (10 min at room temperature) before returning to the incubator wrapped in foil. The following day remaining cell viability was measured by MTT assay (Vybrant MTT, Invitrogen). Results were expressed as the percentage of untreated cells (100% survival) and graphed against the Log₁₀ of the concentration using GraphPad PRISMTM. Non-linear regression was used to determine the concentrations corresponding to a 50% decrease in cell viability (cytotoxicity 50, CC₅₀).

^(b)Concentration of compound inducing 50% of cytotoxicity, as measured by MTT assay, after 10 min of light exposure of the treated cells.

⁽c) Therapeutic index calculated as CC₅₀/IC₅₀ against NDV.

^{-:} Not determined.